If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 24
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Other Skin,
Thoracic Cancers,
Gynecologic Cancers,
Other Gastrointestinal,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Melanoma, Skin,
Esophagus,
Bladder,
Pancreas/Liver,
Prostate,
Skin Cancers,
Kidney,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Colorectal,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Objective
The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
with cemiplimab with or without chemotherapy.
Protocol No
REGENERON-R7075-ONC-2009
A Randomized, Masked, Placebo Controlled, Phase II Trial of Concurrent Chemoradiation with BMX-001 in Patients with Head and Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation
Objective
Study of BMX-001 radioprotector with chemoradiation therapy for H/N cancer patients
Protocol No
NRG-CC013
Categories
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
Cancer,
Kidney,
Skin Cancers,
Stomach,
Uterine,
Lung,
Other Urologic,
Head and Neck Cancers,
Esophagus,
Thoracic Cancers,
Ovary,
Other Gastrointestinal,
Sarcoma,
Gastrointestinal Cancers,
Prostate,
Prostate and Urologic Cancers,
Cervix,
Gynecologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Breast Cancers
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers
Objective
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Participants with Advanced Melanoma or Squamous Cell Head and Neck Cancer
Protocol No
SWOG-S2101
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer,
Other Skin,
Bladder,
Colorectal,
Cervix,
Other Gynecologic,
Breast Cancers,
Esophagus,
Prostate,
Larynx,
Other Gastrointestinal,
Esophagus,
Gynecologic Cancers,
Other Respiratory,
Melanoma, Skin,
Prostate and Urologic Cancers,
Pancreas/Liver,
Eye/Orbital Cancers,
Thoracic Cancers,
Lip, Oral Cavity and Pharynx,
Head and Neck Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Skin Cancers,
Brain and Spine Cancers
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects with Advanced Cancer
Objective
A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer
Protocol No
VOLASTRA-VLS-1488-2201
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
A Phase I/IIa First-in-Human Study of (212Pb)VMT-ALPHA-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
Objective
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Protocol No
VMT-ALPHA-NET-T101